Home > Insider Trading > Filing (0000904454-24-000642)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1590560	Uniqure N.v.	QURE	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1711885	Christian Klemt	C/O Uniqure N.v. Paasheuvelweg 25A Amsterdam P7 11058BP	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2024-12-08	3,672	$0.00	168,509	No	4	A	Direct
Ordinary Shares	Disposition	2024-12-09	1,796	$7.55	166,713	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

Represents performance-based restricted share units ("PRSUs") granted to the Reporting Person on December 8, 2021 under the Issuer's 2014 Share Incentive Plan, as amended and restated, which were earned on December 8, 2024 as the result of the satisfaction of certain performance criteria. Each PRSU represents the contingent right to receive one Ordinary Share.
The shares were sold upon the vesting of PRSUs solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Performance Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.48 to $7.56. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.